QIAGEN Gains FDA Clearance for QIAstat-Dx Bloodstream Panel
GERMANTOWN, Md. and VENLO, Netherlands — September 28, 2026 QIAGEN N.V. announced that the U.S. Food and Drug Administration...
antimicrobial resistance
Advertisement
Armata Pharmaceuticals Highlights AP-SA02 Data at ISSSI 2026
Marina del Rey, California, U.S., September 21, 2026 Armata Pharmaceuticals announced that new data evaluating AP-SA02, its investigational bacteriophage...
SNIPR Advances SNIPR001 Into Phase 2 for E. coli Prevention
COPENHAGEN, Denmark — September 17, 2026 SNIPR announced that the first patient has been enrolled in Part 2 of...
Shionogi Expands Fetroja Role in U.S. Drug-Resistance Preparedness
Osaka, Japan – August 28, 2026 Shionogi & Co., Ltd. announced that the Biomedical Advanced Research and Development Authority...
Innoviva Specialty Therapeutics Products Reach Galien Final
WALTHAM, Mass., August 11, 2026 Innoviva Specialty Therapeutics (IST) announced that three of its infectious disease therapies, XACDURO® (sulbactam/durlobactam),...
Advertisements
QIAGEN Gains FDA Clearance for Bloodstream Infection Testing
Germantown, Maryland, and Venlo, Netherlands, August, 10, 2026 QIAGEN has received U.S. Food and Drug Administration (FDA) clearance for...
Avere Raises $500M to Advance Weekly Oral IL-23 Therapy
San Francisco, California, USA, August 10, 2026 Avere Therapeutics, Inc. has announced a $500 million private placement from a...
Acurx, Leiden Partner to Advance Novel Antibiotic Discovery
Staten Island, New York, USA, August 10, 2026 Acurx Pharmaceuticals, Inc. has announced a new scientific partnership with Leiden...
Biogen Completes RayThera Acquisition to Expand Immunology
Cambridge, Massachusetts, USA, August 8, 2026 Biogen has completed the acquisition of RayThera Inc., a privately held biotechnology company...
Blacksmith Medicines Advances Novel Antibiotic Discovery
San Diego, California, USA, August 8, 2026 Blacksmith Medicines has announced the publication of new research in the Journal...
Advertisement
